Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse

Journal of Clinical Oncology

Volumn 24, Issue 34, 2006, Pages 5373-5380

  Bates, Gaynor J ^a   Fox, Stephen B ^a   Han, Cheng ^a   Leek, Russell D ^a   Garcia, José F ^a   Harris, Adrian L ^a   Banham, Alison H ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; TAMOXIFEN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LONG TERM CARE; LYMPH NODE METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TISSUE MICROARRAY; BREAST TUMOR; CARCINOMA IN SITU; CD4 LYMPHOCYTE COUNT; CHEMISTRY; DISEASE COURSE; FOLLOW UP; LUNG CARCINOMA; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 34247261531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.9584     Document Type: Article

References (22)

1. Thornton AM, Shevach EM: CD4 + CD25 + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287-296, 1998
2. Thompson C, Powrie F: Regulatory T cells. Curr Opin Pharmacol 4:408-414, 2004
3. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761, 2002
4. Ormandy LA, Hillemann T, Wedemeyer H, et al: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457-2464, 2005
5. Ichihara F, Kono K, Takahashi A, et al: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408, 2003
6. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
7. Beyer M, Kochanek M, Darabi K, et al: Reduced frequencies and suppressive function of CD4+ CD25 high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018-2025, 2005
8. Alvaro T, Lejeune M, Salvado MT, et al: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11:1467-1473, 2005
9. Roncador G, Brown PJ, Maestre L, et al: Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. Eur J Immunol 35:1681-1691, 2005
10. Yu P, Lee Y, Liu W, et al: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779-791, 2005
11. Fox SB, Brown P, Han C, et al: Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10:3521-3527, 2004
12. Elston C: Grading of Invasive Carcinoma of the Breast. Edinburgh, United Kingdom, Churchill Livingstone, 1987
13. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
14. Langlands AO, Pocock SJ, Kerr GR, et al: Long-term survival of patients with breast cancer: A study of the curability of the disease. BMJ 2:1247-1251, 1979
15. Toikkanen SP, Kujari HP, Joensuu H: Factors predicting late mortality from breast cancer. Eur J Cancer 27:586-591, 1991
16. Gilchrist KW, Gray R, Fowble B, et al: Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 11:1929-1935, 1993
17. Collett K, Skjaerven R, Maehle BO: The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 48:1-9, 1998
18. Tovey S, Dunne B, Witton CJ, et al: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835-4842, 2005
19. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
20. Polanczyk MJ, Carson BD, Subramanian S, et al: Cutting edge: Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 173:2227-2230, 2004
21. Prieto GA, Rosenstein Y: Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 118:58-65, 2006
22. Emens LA, Reilly RT, Jaffee EM: Breast cancer vaccines: Maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12:1-17, 2005